Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma

Craig C. Hofmeister, MD, Mindy A Bowers, BS, Anissa Bingman, M.S., Gerard Lozanski, M.D., Robert A. Baiocchi, M.D., Ph.D., William Falk, B.S., Don M. Benson, Jr., MD, PhD, Yvonne A Efebera, M.D., Kristina Humphries, M.S., Megan Sell, RN, MS, Carli N Greenfield, RN, MSN, ACNP, Mark E Lustberg, MD, PhD, John L. Vaughn, BS, Christian Tyler Earl, Susan Geyer, PhD, Steven M. Devine, MD

Blood (2012) 120 (21): 4460.

https://doi.org/10.1182/blood.V120.21.4460.4460

Published: 2012

Journal Articles

Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease

Samantha M. Jaglowski, MD, MPH, Sumithira Vasu, MBBS, Susan Geyer, PhD, Anissa Bingman, M.S., Patrick Elder, MS, Jianhua Yu, PhD, William Blum, MD, Rebecca B Klisovic, MD, Sam Penza, MD, Yvonne A Efebera, M.D., Craig C. Hofmeister, MD, Don M. Benson, Jr., MD, PhD, Natarajan Muthusamy, DVM, Ph.D, Steven M. Devine, MD, Leslie A Andritsos, MD, Gerard Lozanski, MD

Blood (2012) 120 (21): 1949.

https://doi.org/10.1182/blood.V120.21.1949.1949

Published: 2012

Journal Articles

Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Blood (2012) 120 (21): 1942.

https://doi.org/10.1182/blood.V120.21.1942.1942

Published: 2012

Journal Articles

A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results

Don M. Benson, Jr., MD, PhD, Adam D Cohen, MD, Nikhil C. Munshi, MD, Sundar Jagannath, MD, Gary Spitzer, MD, Craig C. Hofmeister, MD, Robert Zerbib, Pascale Andre, PhD, Yvonne A Efebera, M.D., Shawna Oxier, Michael A. Caligiuri, M.D.

Blood (2012) 120 (21): 4058.

https://doi.org/10.1182/blood.V120.21.4058.4058

Published: 2012

Journal Articles

Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)

Sumithira Vasu, MBBS, Samantha M. Jaglowski, MD, MPH, Susan Geyer, PhD, Anissa Bingman, M.S., Patrick Elder, M.S., Jianhua Yu, PhD, Leslie A Andritsos, MD, William Blum, MD, Rebecca B Klisovic, MD, Sam Penza, MD, Yvonne A Efebera, M.D., Craig C. Hofmeister, MD, Don M. Benson, Jr., MD, PhD, Natarajan Muthusamy, DVM, Ph.D, Steven M. Devine, MD, Gerard Lozanski, M.D.

Blood (2012) 120 (21): 4192.

https://doi.org/10.1182/blood.V120.21.4192.4192

Published: 2012

Journal Articles

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma

Samantha M. Jaglowski, MD, MPH, Craig C. Hofmeister, MD, Patrick Elder, MS, Sam Penza, MD, Yvonne A Efebera, M.D., Don M. Benson, Jr., MD, PhD, Steven M. Devine, MD, Leslie A Andritsos, MD

Blood (2012) 120 (21): 4286.

https://doi.org/10.1182/blood.V120.21.4286.4286

Published: 2012

Journal Articles

Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma.

Craig C. Hofmeister, MD, Mindy A Bowers, BS, Yvonne A Efebera, M.D., Kristina Humphries, M.S., Don M. Benson, Jr., MD, PhD, Carli N Greenfield, RN, MSN, ACNP, Megan Sell, RN, MS, Steven M. Devine, MD

Blood (2012) 120 (21): 3114.

https://doi.org/10.1182/blood.V120.21.3114.3114

Published: 2012

Journal Articles

miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.

Blood (2012) 120 (21): 2921.

https://doi.org/10.1182/blood.V120.21.2921.2921

Published: 2012

Journal Articles

Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma

Heather McDonagh, B.A., William Falk, B.S., Anissa Bingman, M.S., Susan Geyer, PhD, Don M. Benson, Jr., MD, PhD, Yvonne A Efebera, M.D., Craig C. Hofmeister, MD

Blood (2012) 120 (21): 4978.

https://doi.org/10.1182/blood.V120.21.4978.4978

Published: 2012

Journal Articles

Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens

Simrit Parmar, M.D., Gabriela Rondon, MD, Peter F Thall, PhD, Roland Bassett, Marcos De Lima, MD, Chitra M Hosing, MD, Paolo Anderlini, MD, Partow Kebriaei, MD, Issa Khouri, MD, Prasanth Ganesan, MD, Yvonne A Efebera, M.D., Richard Champlin, MD, Sergio A Giralt, MD

Blood (2011) 118 (21): 1944.

https://doi.org/10.1182/blood.V118.21.1944.1944

Published: 2011

Journal Articles

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.

Don Benson, MD, PhD, Courtney E Bakan, Lana Alghothani, Craig C. Hofmeister, MD, Yvonne A Efebera, M.D., Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Steven M Devine, MD

Blood (2009) 114 (22): 4641.

https://doi.org/10.1182/blood.V114.22.4641.4641

Published: 2009

Journal Articles

Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma.

Craig C Hofmeister, M.D., Don Benson, MD, PhD, Yvonne A Efebera, M.D., Sherif Farag, MBBS, PhD, Michael R. Grever

Blood (2009) 114 (22): 2884.

https://doi.org/10.1182/blood.V114.22.2884.2884

Published: 2009

NARROW

Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma

Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease

Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)

A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results

Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma

Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma.

miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.

Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma

Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.

Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only